HRP20220642T1 - Postupci za liječenje depresije uporabom antagonista receptora oreksina 2 - Google Patents
Postupci za liječenje depresije uporabom antagonista receptora oreksina 2 Download PDFInfo
- Publication number
- HRP20220642T1 HRP20220642T1 HRP20220642TT HRP20220642T HRP20220642T1 HR P20220642 T1 HRP20220642 T1 HR P20220642T1 HR P20220642T T HRP20220642T T HR P20220642TT HR P20220642 T HRP20220642 T HR P20220642T HR P20220642 T1 HRP20220642 T1 HR P20220642T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- use according
- formula
- depression
- disorder
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 3
- 208000020401 Depressive disease Diseases 0.000 title 1
- 102000002512 Orexin Human genes 0.000 title 1
- 108060005714 orexin Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 41
- 230000001430 anti-depressive effect Effects 0.000 claims 4
- 239000000935 antidepressant agent Substances 0.000 claims 4
- 229940005513 antidepressants Drugs 0.000 claims 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 4
- 208000024714 major depressive disease Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 2
- SQOCEMCKYDVLMM-UHFFFAOYSA-N [2-(4,6-dimethylpyrimidin-2-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-[2-fluoro-6-(triazol-2-yl)phenyl]methanone Chemical compound CC1=CC(C)=NC(N2CC3CN(CC3C2)C(=O)C=2C(=CC=CC=2F)N2N=CC=N2)=N1 SQOCEMCKYDVLMM-UHFFFAOYSA-N 0.000 claims 2
- ULXUMMWTPGKPRC-UHFFFAOYSA-N [2-(4,6-dimethylpyrimidin-2-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-[4-methoxy-2-(triazol-2-yl)phenyl]methanone Chemical compound N1=CC=NN1C1=CC(OC)=CC=C1C(=O)N(CC1C2)CC1CN2C1=NC(C)=CC(C)=N1 ULXUMMWTPGKPRC-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 2
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 claims 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 2
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- LILZQJZQERNISU-UHFFFAOYSA-N [2-(4,6-dimethylpyrimidin-2-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-[2-fluoro-6-(triazol-2-yl)phenyl]methanone hydrochloride Chemical compound Cl.Cc1cc(C)nc(n1)N1CC2CN(CC2C1)C(=O)c1c(F)cccc1-n1nccn1 LILZQJZQERNISU-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662306487P | 2016-03-10 | 2016-03-10 | |
| EP17764092.7A EP3426251B1 (en) | 2016-03-10 | 2017-03-09 | Methods of treating depression using orexin-2 receptor antagonists |
| PCT/US2017/021565 WO2017156266A1 (en) | 2016-03-10 | 2017-03-09 | Methods of treating depression using orexin-2 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220642T1 true HRP20220642T1 (hr) | 2022-06-24 |
Family
ID=59776691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220642TT HRP20220642T1 (hr) | 2016-03-10 | 2017-03-09 | Postupci za liječenje depresije uporabom antagonista receptora oreksina 2 |
Country Status (35)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3093291T3 (da) | 2009-10-23 | 2019-07-29 | Janssen Pharmaceutica Nv | Disubstituerede octahy-dropyrrolo [3,4-c]pyrroler som orexinreceptormodulatorer |
| IL288321B2 (en) * | 2016-03-10 | 2025-08-01 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
| US20210169883A1 (en) * | 2018-07-27 | 2021-06-10 | Icahn School Of Medicine At Mount Sinai | Method of treating aggression with orexin receptor antagonists |
| CR20210240A (es) | 2018-11-14 | 2021-06-08 | Janssen Pharmaceutica Nv | Métodos sintéticos mejorados para elaborar compuestos heterocíclicos fusionados como moduladores del receptor de orexina |
| CA3130580A1 (en) | 2019-02-17 | 2020-08-20 | Neurawell Therapeutics | Compositions and methods for treatment of depression and other disorders |
| KR102119231B1 (ko) | 2019-09-05 | 2020-06-04 | 정소진 | 코르크칩을 이용한 신발용 밑창의 제조방법 및 그 제조방법에 의해 제조되는 신발용 밑창, 이를 포함하는 신발 |
| WO2022122009A1 (zh) * | 2020-12-11 | 2022-06-16 | 苏州晶云药物科技股份有限公司 | 吡咯类衍生化合物的晶型及其制备方法 |
| TW202246274A (zh) * | 2021-03-16 | 2022-12-01 | 大陸商上海翰森生物醫藥科技有限公司 | 含氮雜環的多環化合物及其製備方法和應用 |
| CN113393944A (zh) * | 2021-06-17 | 2021-09-14 | 中国科学院长春应用化学研究所 | 基于代谢组学的芪参颗粒治疗慢性心力衰竭的药代动力学-药效动力学分析方法 |
| KR20230074653A (ko) | 2021-11-19 | 2023-05-31 | 고려대학교 세종산학협력단 | 신규 우레아계 또는 카바메이트계 p2x7 수용체 길항제 및 이를 유효성분으로 포함하는 주요 우울 장애의 예방 또는 치료용 약학 조성물 |
| WO2023180556A1 (en) * | 2022-03-24 | 2023-09-28 | Janssen Pharmaceutica Nv | Methods for treating agitation in subjects with mild cognitive impairment or major neurocognition disorder |
| AU2023340064A1 (en) * | 2022-09-14 | 2025-03-20 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Free base crystal form of polycyclic compound of nitrogen-containing heterocycle, and preparation method therefor |
| EP4635949A1 (en) * | 2022-12-12 | 2025-10-22 | Jiangsu NHWA Pharmaceutical Co., Ltd | Substituted tetrahydrocyclopentyl[c]pyrrole derivative, preparation method, intermediate and use thereof |
| JP7626487B2 (ja) * | 2022-12-16 | 2025-02-04 | 株式会社エフアンドエフ | 認知症及び／又はうつ病推定ａｉシステム並びに教師データ作成方法 |
| WO2025003991A1 (en) * | 2023-06-29 | 2025-01-02 | Janssen Pharmaceutica Nv | Method of treating depression using seltorexant |
| CN117338772B (zh) * | 2023-11-22 | 2024-04-09 | 徐州医科大学 | 一种药物组合物及其在制备用于预防和/或治疗重性抑郁障碍的药物中的应用 |
Family Cites Families (150)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7503310A (nl) * | 1975-03-20 | 1976-09-22 | Philips Nv | Verbindingen met antidepressieve werking. |
| GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| IL122296A0 (en) | 1995-06-06 | 1998-04-05 | Abbott Lab | Quinolizinone type compounds |
| GB9519563D0 (en) | 1995-09-26 | 1995-11-29 | Merck Sharp & Dohme | Therapeutic agents |
| WO2000055143A1 (en) | 1999-03-17 | 2000-09-21 | F. Hoffmann-La Roche Ag | Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators |
| US6375897B1 (en) | 2000-02-14 | 2002-04-23 | Ansys Technologies, Inc. | Urine collection cup |
| US6809105B2 (en) | 2000-04-27 | 2004-10-26 | Abbott Laboratories | Diazabicyclic central nervous system active agents |
| MY137020A (en) | 2000-04-27 | 2008-12-31 | Abbott Lab | Diazabicyclic central nervous system active agents |
| CA2408343A1 (en) | 2000-05-11 | 2002-11-07 | Banyu Pharmaceutical Co., Ltd. | N-acyltetrahydroisoquinoline derivatives |
| SE0100326D0 (sv) | 2001-02-02 | 2001-02-02 | Astrazeneca Ab | New compounds |
| WO2002070527A1 (en) | 2001-03-02 | 2002-09-12 | Akzo Nobel N.V. | Mass-selective purification of organometallics |
| MXPA03008109A (es) | 2001-03-07 | 2003-12-12 | Pfizer Prod Inc | Moduladores de la actividad de receptores de quimiocinas. |
| PL367677A1 (en) | 2001-06-28 | 2005-03-07 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| US6455722B1 (en) | 2001-06-29 | 2002-09-24 | Pabu Services, Inc. | Process for the production of pentaerythritol phosphate alcohol |
| GB2383315B (en) | 2001-12-18 | 2005-04-06 | Christopher Donald Clarke | Vehicle imaging system |
| GB0130341D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| DE10226943A1 (de) | 2002-06-17 | 2004-01-08 | Bayer Ag | Phenylaminopyrimidine und ihre Verwendung |
| RU2005103398A (ru) | 2002-07-09 | 2006-06-27 | Актелион Фармасьютикалз Лтд. (Ch) | Производные 7,8,9,10-тетрагидро-6h-азепино-, 6,7,8,9-тетрагидропиридо-и 2,3-дигидро-2h-пирроло-[2,1-b]-хиназолинона |
| AU2003294671A1 (en) | 2002-10-11 | 2004-05-04 | Actelion Pharmaceuticals Ltd. | Sulfonylamino-acetic derivatives and their use as orexin receptor antagonists |
| GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| ATE435210T1 (de) | 2003-03-26 | 2009-07-15 | Actelion Pharmaceuticals Ltd | Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten |
| CA2520839A1 (en) | 2003-04-28 | 2004-11-11 | Actelion Pharmaceuticals Ltd | Quinoxalinone-3- one derivatives as orexin receptor antagonists |
| US20040242641A1 (en) | 2003-05-27 | 2004-12-02 | Buckley Michael J. | (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent |
| WO2005005439A1 (en) | 2003-07-09 | 2005-01-20 | Suven Life Sciences Limited | Benzothiazino indoles |
| TW200507850A (en) | 2003-07-25 | 2005-03-01 | Kyowa Hakko Kogyo Kk | Pharmaceutical composition |
| WO2005023231A1 (en) | 2003-09-10 | 2005-03-17 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Polypyrimidine tract binding protein promotes insulin secretory granule biogenesis |
| US20050065178A1 (en) | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
| US7399765B2 (en) | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| PL1691811T3 (pl) | 2003-12-11 | 2014-12-31 | Sunovion Pharmaceuticals Inc | Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji |
| HUP0400405A3 (en) | 2004-02-10 | 2009-03-30 | Sanofi Synthelabo | Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
| HRP20150371T1 (hr) | 2004-03-01 | 2015-05-08 | Actelion Pharmaceuticals Ltd. | Supstituirani derivati 1,2,3,4-tetrahidroizokinolina |
| US7435831B2 (en) | 2004-03-03 | 2008-10-14 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
| AU2005219438B2 (en) | 2004-03-03 | 2011-02-17 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
| EP1781670A1 (en) | 2004-07-22 | 2007-05-09 | Cumbre Pharmaceuticals Inc. | Rifamycin derivatives for treating microbial infections |
| US20070270417A1 (en) | 2004-07-22 | 2007-11-22 | Glaxo Group Limited | Antibacterial Agents |
| FR2874011B1 (fr) | 2004-08-03 | 2007-06-15 | Sanofi Synthelabo | Derives de sulfonamides, leur preparation et leur application en therapeutique |
| EP1807390A4 (en) | 2004-11-04 | 2008-07-02 | Neurogen Corp | ARYL ALKYL UREA AS CB1 ANTAGONISTS |
| WO2006056848A1 (en) | 2004-11-24 | 2006-06-01 | Pfizer Limited | Octahydropyrrolo[3,4-c]pyrrole derivatives |
| DE102004061344A1 (de) | 2004-12-20 | 2006-07-06 | Siemens Ag | Verfahren zur sicheren Auslegung eines Systems, zugehörige Systemkomponente und Software |
| RU2007146444A (ru) | 2005-05-13 | 2009-06-20 | Лексикон Фармасьютикалз, Инк. (Us) | Полициклические соединения и способы их применения |
| WO2006124897A2 (en) | 2005-05-13 | 2006-11-23 | Lexicon Genetics Incorporated | Methods and compositions for improving cognition |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| US20080175795A1 (en) | 2005-06-30 | 2008-07-24 | Bexel Pharmaceuticals, Inc. | Novel derivatives of amino acids for treatment of obesity and related disorders |
| GB0514018D0 (en) | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
| CA2620124A1 (en) | 2005-08-26 | 2007-03-01 | Merck And Co., Inc. | Diazaspirodecane orexin receptor antagonists |
| FR2896798A1 (fr) | 2006-01-27 | 2007-08-03 | Sanofi Aventis Sa | Derives de sulfonamides, leur preparation et leur application en therapeutique |
| FR2896799B1 (fr) | 2006-02-02 | 2008-03-28 | Sanofi Aventis Sa | Derives de sulfonamides, leur preparation et leur application en therapeutique |
| US7553836B2 (en) | 2006-02-06 | 2009-06-30 | Bristol-Myers Squibb Company | Melanin concentrating hormone receptor-1 antagonists |
| WO2007126934A2 (en) | 2006-03-29 | 2007-11-08 | Merck & Co., Inc. | Amidoethylthioether orexin receptor antagonists |
| US8685961B2 (en) | 2006-03-29 | 2014-04-01 | Merck Sharp & Dohme Corp. | Diazepan orexin receptor antagonists |
| CA2647077A1 (en) | 2006-04-26 | 2007-11-01 | Actelion Pharmaceuticals Ltd | Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists |
| WO2007146761A2 (en) | 2006-06-12 | 2007-12-21 | Neurogen Corporation | Diaryl pyrimidinones and related compounds |
| US8618102B2 (en) | 2006-07-14 | 2013-12-31 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
| AU2007272795A1 (en) | 2006-07-14 | 2008-01-17 | Merck & Co., Inc. | 2-substituted proline bis-amide orexin receptor antagonists |
| EP2049529B1 (en) | 2006-07-14 | 2010-08-11 | Merck Sharp & Dohme Corp. | Substituted diazepan orexin receptor antagonists |
| PL2069332T3 (pl) | 2006-08-15 | 2011-07-29 | Actelion Pharmaceuticals Ltd | Związki azetydynowe jako antagoniści receptorów oreksynowych |
| CA2659352A1 (en) | 2006-08-28 | 2008-03-06 | Actelion Pharmaceuticals Ltd | 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulene derivatives as orexin receptor antagonists |
| ES2345130T3 (es) | 2006-09-18 | 2010-09-15 | F. Hoffmann-La Roche Ag | Derivados de octahidropirrolo(3,4-c)pirrol y su uso como antiviricos. |
| EP2079690B1 (en) | 2006-09-29 | 2010-09-15 | Actelion Pharmaceuticals Ltd. | 3-aza-bicyclo[3.1.0]hexane derivatives |
| WO2008052139A2 (en) | 2006-10-25 | 2008-05-02 | Somaxon Pharmaceuticals, Inc. | Ultra low dose doxepin and methods of using the same to treat sleep disorders |
| CA2668811A1 (en) | 2006-11-07 | 2008-06-05 | Lexicon Pharmaceuticals, Inc. | Methods of treating cognitive impairment and dementia |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| WO2008070795A2 (en) | 2006-12-06 | 2008-06-12 | Somaxon Pharmaceuticals, Inc. | Combination therapy using low-dose doxepin for the improvement of sleep |
| RU2009127842A (ru) | 2006-12-22 | 2011-01-27 | Актелион Фармасьютиклз Лтд (Ch) | ПРОИЗВОДНЫЕ 5,6,7,8-ТЕТРАГИДРОИМИДАЗО[1.5-а]ПИРАЗИНА |
| CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
| JP2010525077A (ja) | 2007-04-25 | 2010-07-22 | ブリストル−マイヤーズ スクイブ カンパニー | 非塩基性メラニン凝集ホルモン受容体−１アンタゴニスト |
| AU2008255005B2 (en) | 2007-05-18 | 2013-05-02 | Merck Sharp & Dohme Corp. | OXO bridged diazepan orexin receptor antagonists |
| FR2918061B1 (fr) | 2007-06-28 | 2010-10-22 | Sanofi Aventis | Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique. |
| GB0712888D0 (en) | 2007-07-03 | 2007-08-15 | Glaxo Group Ltd | Novel compounds |
| EA201070091A1 (ru) | 2007-07-03 | 2010-06-30 | Глэксо Груп Лимитед | Производные пиперидина, пригодные в качестве антагонистов рецептора орексина |
| CA2691373A1 (en) | 2007-07-03 | 2009-01-08 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.3.0]octane compounds |
| US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| WO2009011775A1 (en) | 2007-07-13 | 2009-01-22 | Merck & Co., Inc. | Amidoethyl alkylamino orexin receptor antagonists |
| FR2918986B1 (fr) | 2007-07-19 | 2009-09-04 | Sanofi Aventis Sa | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
| NZ583487A (en) | 2007-07-27 | 2011-09-30 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.3.0]octane derivatives |
| AU2008281876A1 (en) | 2007-08-02 | 2009-02-05 | F. Hoffmann-La Roche Ag | Monoamide derivatives as orexin receptor antagonists |
| CA2694993A1 (en) | 2007-08-15 | 2009-02-19 | Actelion Pharmaceuticals Ltd | 1,2-diamido-ethylene derivatives |
| EP2207778A2 (en) | 2007-09-24 | 2010-07-21 | Actelion Pharmaceuticals Ltd. | Pyrrolidines and piperidines as orexin receptor antagonists |
| US8362009B2 (en) | 2007-10-29 | 2013-01-29 | Merck Sharp & Dohme Corp. | Substituted diazepan orexin receptor antagonists |
| EP2058001A1 (en) | 2007-11-08 | 2009-05-13 | Crossbeta Biosciences B.V. | Enhancement of immunogenicity of antigens |
| CA2705411A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Heteroaryl derivatives as orexin receptor antagonists |
| BRPI0821676A2 (pt) | 2007-12-21 | 2015-06-16 | Astrazeneca Ab | Composto, composição farmacêutica, e, processo para a preparação dos compostos. |
| GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
| JP6106361B2 (ja) | 2008-05-27 | 2017-03-29 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 睡眠障害および他の障害のための方法および組成物 |
| CN102083820B (zh) | 2008-07-29 | 2013-07-17 | 弗·哈夫曼-拉罗切有限公司 | 作为食欲肽拮抗剂的吡咯烷-3-基甲基-胺 |
| AR072899A1 (es) | 2008-08-07 | 2010-09-29 | Merck Sharp & Dohme | Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad. |
| US20100267730A1 (en) | 2008-10-09 | 2010-10-21 | Giuseppe Alvaro | Novel compounds |
| US8093255B2 (en) | 2008-10-09 | 2012-01-10 | Glaxo Group Limited | Imidazo[1,2-A]pyrimidines as orexin receptor antagonists |
| US8129384B2 (en) | 2008-10-09 | 2012-03-06 | Glaxo Group Limited | Imidazo[1,2-a]pyrazines as orexin receptor antagonists |
| JP2012506375A (ja) | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | ２，５−二置換ピペリジンオレキシン受容体アンタゴニスト |
| WO2010048017A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | Disubstituted azepan orexin receptor antagonists |
| WO2010048010A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
| WO2010048013A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted morpholine orexin receptor antagonists |
| CA2739919A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,4-disubstituted pyrrolidine orexin receptor antagonists |
| US8357700B2 (en) | 2008-10-21 | 2013-01-22 | Merck Sharp & Dohme Corp. | 2,3-disubstituted piperidine orexin receptor antagonists |
| EP2349262B1 (en) | 2008-10-30 | 2014-06-25 | Merck Sharp & Dohme Corp. | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists |
| CN102272103B (zh) | 2008-10-30 | 2015-10-21 | 默沙东公司 | 异烟酰胺食欲素受体拮抗剂 |
| US8703770B2 (en) | 2008-10-30 | 2014-04-22 | Merck Sharp & Dohme Corp. | Pyridazine carboxamide orexin receptor antagonists |
| JP2012509912A (ja) | 2008-11-26 | 2012-04-26 | グラクソ グループ リミテッド | 新規の化合物 |
| EP2358711A1 (en) | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| WO2010060471A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| UY32277A (es) | 2008-12-02 | 2010-05-31 | Glaxo Group Ltd | Derivados de n-{[1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4.1.0-il}metil}-2heteroarilamina y uso de los mismos |
| BRPI0922353A2 (pt) | 2008-12-02 | 2018-06-05 | Glaxo Group Ltd | Derivados de n-{[(1r,4s, 6r-3- (2-piridinilcarbonil) - 3azabiciclo [4.1.0] hept-4-il] metil}-2-heteroarilamina e usos dos mesmos |
| GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
| US20100214135A1 (en) | 2009-02-26 | 2010-08-26 | Microsoft Corporation | Dynamic rear-projected user interface |
| EP2421850A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | 3 -azabicyclo [4.1.0]heptanes used as orexin antagonists |
| JP2013502448A (ja) | 2009-08-24 | 2013-01-24 | グラクソ グループ リミテッド | オレキシンアンタゴニストとして用いられるピペリジン誘導体 |
| EP2470523A1 (en) | 2009-08-24 | 2012-07-04 | Glaxo Group Limited | 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder |
| JP5848251B2 (ja) | 2009-10-23 | 2016-01-27 | ヤンセン ファーマシューティカ エヌ．ベー． | オレキシン受容体調節因子としての縮合複素環式化合物 |
| DK3093291T3 (da) | 2009-10-23 | 2019-07-29 | Janssen Pharmaceutica Nv | Disubstituerede octahy-dropyrrolo [3,4-c]pyrroler som orexinreceptormodulatorer |
| WO2011050200A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| US8877773B2 (en) | 2009-10-24 | 2014-11-04 | Indiana University Research And Technology Corporation | Methods for treating chronic obstructive pulmonary disease |
| TWI410630B (zh) | 2009-11-10 | 2013-10-01 | Ct Lab Inc | 一種用以治療與食慾素受體１、食慾素受體２、體抑素受體２或多巴胺ｄ２ｌ受體相關之疾病的方法和組合物 |
| AU2010336386B2 (en) | 2009-12-23 | 2016-01-21 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
| SG191103A1 (en) | 2010-12-17 | 2013-08-30 | Taisho Pharmaceutical Co Ltd | Pyrazole derivative |
| WO2012089607A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors |
| WO2012089606A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists |
| US9586962B2 (en) | 2011-04-20 | 2017-03-07 | Janssen Pharmaceutica Nv | Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators |
| EP2708537A4 (en) | 2011-05-10 | 2014-10-01 | Taisho Pharmaceutical Co Ltd | HETEROAROMATIC RING DERIVATIVE |
| EP2730573A4 (en) | 2011-07-05 | 2014-12-03 | Taisho Pharmaceutical Co Ltd | METHYLPIPERIDINDERIVAT |
| US9029364B2 (en) | 2011-10-21 | 2015-05-12 | Merck Sharp & Dohme Corp. | 2,5-disubstituted thiomorpholine orexin receptor antagonists |
| EP2811997B1 (en) | 2012-02-07 | 2018-04-11 | Eolas Therapeutics Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| WO2013126856A1 (en) | 2012-02-23 | 2013-08-29 | Vanderbilt University | Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| CN104364238A (zh) | 2012-06-15 | 2015-02-18 | 大正制药株式会社 | 支链烷基杂芳环衍生物 |
| JP2014015452A (ja) | 2012-06-15 | 2014-01-30 | Taisho Pharmaceutical Co Ltd | ピラゾール誘導体を含有する医薬 |
| SG11201408327XA (en) | 2012-06-15 | 2015-02-27 | Taisho Pharmaceutical Co Ltd | Heteroaromatic methyl cyclic amine derivative |
| JP2014111586A (ja) | 2012-11-09 | 2014-06-19 | Taisho Pharmaceutical Co Ltd | ヘテロ芳香環誘導体を含有する医薬 |
| WO2014085208A1 (en) | 2012-11-27 | 2014-06-05 | Merck Sharp & Dohme Corp. | 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists |
| JP2016028017A (ja) | 2012-12-13 | 2016-02-25 | 大正製薬株式会社 | フッ素置換ピペリジン化合物 |
| JP2014141480A (ja) | 2012-12-28 | 2014-08-07 | Taisho Pharmaceutical Co Ltd | メチルピペリジン誘導体を含有する医薬 |
| TWI621618B (zh) | 2013-03-13 | 2018-04-21 | 比利時商健生藥品公司 | 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途 |
| WO2015018027A1 (en) | 2013-08-08 | 2015-02-12 | Merck Sharp & Dohme Corp. | Thiazole orexin receptor antagonists |
| AU2014360452C1 (en) | 2013-12-03 | 2019-05-16 | Intra-Cellular Therapies, Inc. | Novel methods |
| WO2015088865A1 (en) | 2013-12-09 | 2015-06-18 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-4-methyl orexin receptor antagonists |
| JP2015131802A (ja) | 2013-12-13 | 2015-07-23 | 大正製薬株式会社 | 分岐鎖アルキルヘテロ芳香環誘導体を含有する医薬 |
| JP5930010B2 (ja) | 2013-12-13 | 2016-06-08 | 大正製薬株式会社 | ヘテロ芳香環メチル環状アミン誘導体を含有する医薬 |
| WO2015095108A1 (en) * | 2013-12-18 | 2015-06-25 | Merck Sharp & Dohme Corp. | Thioether-piperidinyl orexin receptor antagonists |
| TW201613891A (en) | 2014-02-12 | 2016-04-16 | Eolas Therapeutics Inc | Substituted prolines / piperidines as orexin receptor antagonists |
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| JP2017100950A (ja) | 2014-04-04 | 2017-06-08 | 大正製薬株式会社 | オキソ複素環誘導体 |
| JP2017100951A (ja) | 2014-04-04 | 2017-06-08 | 大正製薬株式会社 | オキサゾリジノン及びオキサジナノン誘導体 |
| CN105377840B (zh) | 2014-05-28 | 2017-12-22 | 杭州普晒医药科技有限公司 | 一种二氮杂环庚烷化合物的盐及其晶型与无定型物 |
| WO2016025669A1 (en) | 2014-08-13 | 2016-02-18 | Eolas Therapeutics, Inc. | Difluoropyrrolidines as orexin receptor modulators |
| US20160051533A1 (en) | 2014-08-20 | 2016-02-25 | Ladd Research LLC | Diagnosis and pharmacological treatment of seasonal affective disorder and symptoms of seasonality |
| GB201415569D0 (en) | 2014-09-03 | 2014-10-15 | C4X Discovery Ltd | Therapeutic Compounds |
| WO2017012502A1 (en) | 2015-07-17 | 2017-01-26 | Sunshine Lake Pharma Co., Ltd. | Substituted quinazoline compounds and preparation and uses thereof |
| GB201601703D0 (en) | 2016-01-29 | 2016-03-16 | C4X Discovery Ltd | Therapeutic compounds |
| IL288321B2 (en) * | 2016-03-10 | 2025-08-01 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
| GB201820458D0 (en) | 2018-12-14 | 2019-01-30 | Heptares Therapeutics Ltd | Ox1 antagonists |
-
2017
- 2017-03-09 IL IL288321A patent/IL288321B2/en unknown
- 2017-03-09 CA CA3016706A patent/CA3016706A1/en active Pending
- 2017-03-09 KR KR1020187026455A patent/KR102448342B1/ko active Active
- 2017-03-09 MX MX2018010852A patent/MX2018010852A/es unknown
- 2017-03-09 MA MA43468A patent/MA43468B1/fr unknown
- 2017-03-09 MD MDE20190089T patent/MD3426251T2/ro unknown
- 2017-03-09 CR CR20180433A patent/CR20180433A/es unknown
- 2017-03-09 IL IL319248A patent/IL319248A/en unknown
- 2017-03-09 KR KR1020227033141A patent/KR102559922B1/ko active Active
- 2017-03-09 AU AU2017231828A patent/AU2017231828B2/en active Active
- 2017-03-09 SI SI201731154T patent/SI3426251T1/sl unknown
- 2017-03-09 EA EA201891930A patent/EA201891930A1/ru unknown
- 2017-03-09 HR HRP20220642TT patent/HRP20220642T1/hr unknown
- 2017-03-09 RS RS20220487A patent/RS63296B1/sr unknown
- 2017-03-09 PL PL17764092.7T patent/PL3426251T3/pl unknown
- 2017-03-09 US US15/454,628 patent/US10828302B2/en active Active
- 2017-03-09 PT PT177640927T patent/PT3426251T/pt unknown
- 2017-03-09 MA MA43817A patent/MA43817B1/fr unknown
- 2017-03-09 JP JP2018547296A patent/JP7066622B2/ja active Active
- 2017-03-09 ES ES17764092T patent/ES2913469T3/es active Active
- 2017-03-09 SG SG11201807597UA patent/SG11201807597UA/en unknown
- 2017-03-09 KR KR1020237025023A patent/KR20230116948A/ko not_active Ceased
- 2017-03-09 WO PCT/US2017/021565 patent/WO2017156266A1/en not_active Ceased
- 2017-03-09 MY MYPI2018703204A patent/MY197558A/en unknown
- 2017-03-09 CA CA2960253A patent/CA2960253A1/en active Pending
- 2017-03-09 HU HUE17764092A patent/HUE058759T2/hu unknown
- 2017-03-09 EP EP17764092.7A patent/EP3426251B1/en active Active
- 2017-03-09 PH PH1/2018/501903A patent/PH12018501903B1/en unknown
- 2017-03-09 CN CN201780016369.3A patent/CN108883110B/zh active Active
- 2017-03-09 KR KR1020257016875A patent/KR20250083571A/ko active Pending
- 2017-03-09 CN CN202210483090.9A patent/CN115154470B/zh active Active
- 2017-03-09 DK DK17764092.7T patent/DK3426251T3/da active
- 2017-03-09 BR BR112018067906A patent/BR112018067906A2/pt not_active Application Discontinuation
- 2017-03-09 UA UAA201810094A patent/UA125873C2/uk unknown
- 2017-03-09 LT LTEPPCT/US2017/021565T patent/LT3426251T/lt unknown
- 2017-03-09 EP EP22168101.8A patent/EP4091634A1/en active Pending
- 2017-03-09 SM SM20220239T patent/SMT202200239T1/it unknown
-
2018
- 2018-08-29 IL IL261461A patent/IL261461B/en unknown
- 2018-09-05 CL CL2018002533A patent/CL2018002533A1/es unknown
- 2018-09-06 NI NI201800086A patent/NI201800086A/es unknown
- 2018-09-10 SV SV2018005740A patent/SV2018005740A/es unknown
- 2018-09-12 CO CONC2018/0009561A patent/CO2018009561A2/es unknown
- 2018-09-18 DO DO2018000196A patent/DOP2018000196A/es unknown
-
2020
- 2020-11-09 US US17/092,725 patent/US11241432B2/en active Active
-
2021
- 2021-08-10 JP JP2021130744A patent/JP2021181474A/ja not_active Withdrawn
- 2021-12-15 US US17/551,955 patent/US12201634B2/en active Active
-
2022
- 2022-06-15 CY CY20221100412T patent/CY1125247T1/el unknown
- 2022-11-09 JP JP2022179528A patent/JP7534373B2/ja active Active
- 2022-11-29 AU AU2022279416A patent/AU2022279416C1/en active Active
-
2024
- 2024-02-13 JP JP2024019351A patent/JP2024056847A/ja active Pending
-
2025
- 2025-01-10 US US19/016,620 patent/US20250221992A1/en active Pending
- 2025-05-20 AU AU2025203695A patent/AU2025203695A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220642T1 (hr) | Postupci za liječenje depresije uporabom antagonista receptora oreksina 2 | |
| JP2019511489A5 (enExample) | ||
| IS8503A (is) | Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar | |
| HRP20201949T1 (hr) | 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji | |
| SG10201903578VA (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| HRP20110539T1 (hr) | PIRIDINO[3,4-b]PIRAZINONI | |
| CR10419A (es) | Derivados de Pirazolo [3,4-D]-Pirimidina útiles para tratar trastornos respiratorios | |
| NO20075641L (no) | Kroman og kromenderivater og ders anvendelse | |
| TW200726765A (en) | Triazolopyridine cannabinoid receptor 1 antagonists | |
| JP2016538313A5 (enExample) | ||
| JP2009524676A5 (enExample) | ||
| EA200901505A1 (ru) | 3,6-дизамещенные имидазо[1,2-b]пиридазины и 3,5-дизамещенные пиразоло[1,5-a]пиримидины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| NO20080670L (no) | Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister | |
| WO2018060463A3 (en) | Treatment of prostate cancer | |
| ECSP056115A (es) | ANTAGONISTAS DEL RECEPTOR A2a DE 2-ALQUINIL- Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA ADENOSINA | |
| NO20081924L (no) | 7-[2-[4-(6-fluor-3-metyl-1,2-benzisoksazol-5-yl)-1-pipera-zinyl]etyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-c]-pyrimidin-5-amin | |
| PE20090944A1 (es) | PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT | |
| AR042148A1 (es) | Derivados de indazol como antagonistas de crf | |
| BR112013031121A2 (pt) | composto de acordo com a fórmula i a v, ou um sal farmaceuticamente aceitável, solvato, polimorfo, ou pró-droga do mesmo; composto; polimorfo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2-il)acetamida (fórmula i); ingrediente ativo constituído do mesmo; composição farmacêutica; polimorfo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)1h-pirrol-3-il)tiazol-2-il)fenil)acetamida (fórmula i); ingrediente ativo constituído do mesmo; uso de um composto ou sal farmaceuticamente aceitável, solvato, polimorfo ou pró-droga do mesmo e uso de um polimorfo ou ingrediente ativo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2il)tiazol-2-il)fenil)acetamida (fórmula i) e uso de um polimorfo ou ingrediente ativo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h1pirrol-3-il)tiazol-2-il)fenil)acetamida(fórmula i) na fabricação de um medicamento | |
| RU2014144951A (ru) | Новое 1-замещенное производное индазола | |
| MX388825B (es) | Uso y dosificacion de agentes terapeuticos para endometriosis. | |
| HRP20201152T1 (hr) | Kondenzirani benzazepin za liječenje mucanja | |
| PE20061318A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos | |
| EA201070916A1 (ru) | Двойные фармакофоры - pde4-мускариновые антагонисты | |
| AR037611A1 (es) | Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden |